Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session.
Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $32
Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and lowers the price target from $35 to $32.
SVB Leerink Maintains Outperform on Vir Biotechnology, Raises Price Target to $45
SVB Leerink analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $40 to $45.
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
This Addiction Drug Shows Some Potential Against Long COVID Symptoms
Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection.
Vir Biotech Secures US Government Contract For Influenza & Other Infectious Disease Candidates
With its COVID-19 monoclonal antibody sidelined in the U.S. since April and plans for full approval no longer in the cards, Vir…
Vir Biotechnology Announces First Patient Dosed In The Phase 2 SOLSTICE Trial Evaluating VIR-2218 And VIR-3434 For The Treatment Of Chronic Hepatitis D Virus Infection
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of
This Hepatitis Stock Has ‘Multiple Paths To Value Creation,’ Expects To Double, Bullish Analyst Predicts
SVB Leerink initiated coverage on Vir Biotechnology Inc (NASDAQ:VIR) with an Outperform rating and a price target of $40, with an investment…